A genomic enhancer signature associates with hepatocellular carcinoma prognosis
Ah-Jung Jeon,
Chukwuemeka George Anene-Nzelu,
Yue-Yang Teo,
Shay Lee Chong,
Karthik Sekar,
Lingyan Wu,
Sin-Chi Chew,
Jianbin Chen,
Raden Indah Kendarsari,
Hannah Lai,
Wen Huan Ling,
Neslihan Arife Kaya,
Jia Qi Lim,
Alexander Yaw Fui Chung,
Peng-Chung Cheow,
Juinn Huar Kam,
Krishnakumar Madhavan,
Alfred Kow,
Iyer Shridhar Ganpathi,
Tony Kiat Hon Lim,
Wei-Qiang Leow,
Shihleone Loong,
Tracy Jiezhen Loh,
Wei Keat Wan,
Gwyneth Shook Ting Soon,
Yin Huei Pang,
Boon Koon Yoong,
Diana Bee-Lan Ong,
Jasmine Lim,
Vanessa H. de Villa,
Rouchelle D. dela Cruz,
Rawisak Chanwat,
Jidapa Thammasiri,
Glenn K. Bonney,
Brian K.P. Goh,
Roger Sik Yin Foo,
Pierce Kah-Hoe Chow
Affiliations
Ah-Jung Jeon
Program in Clinical and Translational Liver Cancer Research, Division of Medical Science, National Cancer Center Singapore, Singapore
Chukwuemeka George Anene-Nzelu
Cardiovascular Disease Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Montreal Heart Institute, Montreal, Quebec, Canada; Department of Medicine, University of Montreal, Quebec, Canada
Yue-Yang Teo
Program in Clinical and Translational Liver Cancer Research, Division of Medical Science, National Cancer Center Singapore, Singapore
Shay Lee Chong
Program in Clinical and Translational Liver Cancer Research, Division of Medical Science, National Cancer Center Singapore, Singapore
Karthik Sekar
Program in Clinical and Translational Liver Cancer Research, Division of Medical Science, National Cancer Center Singapore, Singapore
Lingyan Wu
Program in Clinical and Translational Liver Cancer Research, Division of Medical Science, National Cancer Center Singapore, Singapore
Sin-Chi Chew
Program in Clinical and Translational Liver Cancer Research, Division of Medical Science, National Cancer Center Singapore, Singapore
Jianbin Chen
Genome Institute of Singapore, Agency for Science, Technology and Research (A∗STAR), Singapore
Raden Indah Kendarsari
Genome Institute of Singapore, Agency for Science, Technology and Research (A∗STAR), Singapore
Hannah Lai
Genome Institute of Singapore, Agency for Science, Technology and Research (A∗STAR), Singapore
Wen Huan Ling
Program in Clinical and Translational Liver Cancer Research, Division of Medical Science, National Cancer Center Singapore, Singapore
Neslihan Arife Kaya
Genome Institute of Singapore, Agency for Science, Technology and Research (A∗STAR), Singapore
Jia Qi Lim
Genome Institute of Singapore, Agency for Science, Technology and Research (A∗STAR), Singapore
Alexander Yaw Fui Chung
Department of Hepatopancreatobiliary and Transplant Surgery, National Cancer Centre Singapore and Singapore General Hospital, Singapore; Academic Clinical Programme for Surgery, Duke-NUS Medical School, Singapore
Peng-Chung Cheow
Department of Hepatopancreatobiliary and Transplant Surgery, National Cancer Centre Singapore and Singapore General Hospital, Singapore; Academic Clinical Programme for Surgery, Duke-NUS Medical School, Singapore
Juinn Huar Kam
Department of Hepatopancreatobiliary and Transplant Surgery, National Cancer Centre Singapore and Singapore General Hospital, Singapore; Academic Clinical Programme for Surgery, Duke-NUS Medical School, Singapore
Krishnakumar Madhavan
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, University Surgical Cluster, National University Health System, Singapore
Alfred Kow
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, University Surgical Cluster, National University Health System, Singapore
Iyer Shridhar Ganpathi
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, University Surgical Cluster, National University Health System, Singapore
Tony Kiat Hon Lim
Department of Anatomical Pathology, Singapore General Hospital, Singapore
Wei-Qiang Leow
Department of Anatomical Pathology, Singapore General Hospital, Singapore
Shihleone Loong
Department of Anatomical Pathology, Singapore General Hospital, Singapore
Tracy Jiezhen Loh
Department of Anatomical Pathology, Singapore General Hospital, Singapore
Wei Keat Wan
Department of Anatomical Pathology, Singapore General Hospital, Singapore
Gwyneth Shook Ting Soon
Department of Pathology, National University Hospital, Singapore
Yin Huei Pang
Department of Pathology, National University Hospital, Singapore
Boon Koon Yoong
Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
Diana Bee-Lan Ong
Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
Jasmine Lim
Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
Vanessa H. de Villa
Department of Surgery and Center for Liver Health and Transplantation, The Medical City, Pasig City, Philippines
Rouchelle D. dela Cruz
Department of Laboratory Medicine and Pathology, The Medical City, Pasig City, Philippines
Rawisak Chanwat
Hepato-Pancreato-Biliary Surgery Unit, Department of Surgery, National Cancer Institute, Bangkok, Thailand
Jidapa Thammasiri
Division of Pathology, National Cancer Institute, Thailand
Glenn K. Bonney
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, University Surgical Cluster, National University Health System, Singapore
Brian K.P. Goh
Department of Hepatopancreatobiliary and Transplant Surgery, National Cancer Centre Singapore and Singapore General Hospital, Singapore; Academic Clinical Programme for Surgery, Duke-NUS Medical School, Singapore
Roger Sik Yin Foo
Cardiovascular Disease Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Genome Institute of Singapore, Agency for Science, Technology and Research (A∗STAR), Singapore; Cardiovascular Research Institute, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
Pierce Kah-Hoe Chow
Program in Clinical and Translational Liver Cancer Research, Division of Medical Science, National Cancer Center Singapore, Singapore; Department of Hepatopancreatobiliary and Transplant Surgery, National Cancer Centre Singapore and Singapore General Hospital, Singapore; Academic Clinical Programme for Surgery, Duke-NUS Medical School, Singapore; Corresponding author. Address: National Cancer Centre Singapore, 30 Hospital Boulevard, Singapore 168583, Singapore. Tel.: +65-63065424.
Background & Aims: Lifestyle and environmental-related exposures are important risk factors for hepatocellular carcinoma (HCC), suggesting that epigenetic dysregulation significantly underpins HCC. We profiled 30 surgically resected tumours and the matched adjacent normal tissues to understand the aberrant epigenetic events associated with HCC. Methods: We identified tumour differential enhancers and the associated genes by analysing H3K27 acetylation (H3K27ac) chromatin immunoprecipitation sequencing (ChIP-seq) and Hi-C/HiChIP data from the resected tumour samples of 30 patients with early-stage HCC. This epigenome dataset was analysed with previously reported genome and transcriptome data of the overlapping group of patients from the same cohort. We performed patient-specific differential expression testing using multiregion sequencing data to identify genes that undergo both enhancer and gene expression changes. Based on the genes selected, we identified two patient groups and performed a recurrence-free survival analysis. Results: We observed large-scale changes in the enhancer distribution between HCC tumours and the adjacent normal samples. Many of the gain-in-tumour enhancers showed corresponding upregulation of the associated genes and vice versa, but much of the enhancer and gene expression changes were patient-specific. A subset of the upregulated genes was activated in a subgroup of patients’ tumours. Recurrence-free survival analysis revealed that the patients with a more robust upregulation of those genes showed a worse prognosis. Conclusions: We report the genomic enhancer signature associated with differential prognosis in HCC. Findings that cohere with oncofoetal reprogramming in HCC were underpinned by genome-wide enhancer rewiring. Our results present the epigenetic changes in HCC that offer the rational selection of epigenetic-driven gene targets for therapeutic intervention or disease prognostication in HCC. Impact and Implications: Lifestyle and environmental-related exposures are the important risk factors of hepatocellular carcinoma (HCC), suggesting that tumour-associated epigenetic dysregulations may significantly underpin HCC. We profiled tumour tissues and their matched normal from 30 patients with early-stage HCC to study the dysregulated epigenetic changes associated with HCC. By also analysing the patients’ RNA-seq and clinical data, we found the signature genes – with epigenetic and transcriptomic dysregulation – associated with worse prognosis. Our findings suggest that systemic approaches are needed to consider the surrounding cellular environmental and epigenetic changes in HCC tumours.